Sugi Tomiyuki, Mita Mitsuo, Yasu Takeo, Kubo Kana, Kushi Ryota, Hanai Homare, Ohara Shin, Uchida Tomoyuki, Inoue Morihiro, Hagihara Masao
Department of Pharmacy, Eiju General Hospital, Taito-ku, Japan.
Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan.
J Clin Pharm Ther. 2022 Apr;47(4):477-482. doi: 10.1111/jcpt.13568. Epub 2021 Nov 14.
It was previously reported that the incidence of lenalidomide (LEN)-induced skin rash is reduced by administration of bortezomib (BOR) prior to LEN administration in patients with multiple myeloma (MM). Therefore, we investigated whether LEN-induced skin rash is affected by the duration of BOR administration and the dosing interval between BOR and LEN administration.
A retrospective investigation was conducted among MM patients who received BOR treatment prior to LEN treatment in Eiju General Hospital from May 2010 to December 2020. We investigated whether the BOR administration duration and interval duration from the completion of BOR administration to the initial LEN administration affect the development of LEN-induced skin rash.
Twenty-eight of the 81 patients exhibited LEN-induced skin rash (34.6%). The administered duration, but not the interval, was significantly longer in the group without skin rash. Cut-off values were set for the duration of administration and interval, which were 35 days and 30 days, respectively. Multivariate analysis was performed on patients which are administered duration of more than 35 days and intervals of less than 30 days, and those who are not applicable. A significant difference was observed in the incidence of skin rash for each factor.
The risk of reduced LEN-induced skin rash is affected not only by the presence of prior BOR administration, but also by the duration of BOR and the interval from the completion of BOR to the initial LEN administration.
此前有报道称，在多发性骨髓瘤（MM）患者中，在使用来那度胺（LEN）之前给予硼替佐米（BOR）可降低LEN诱发皮疹的发生率。因此，我们研究了BOR的给药持续时间以及BOR与LEN给药之间的给药间隔是否会影响LEN诱发的皮疹。
对2010年5月至2020年12月在Eiju综合医院接受LEN治疗前接受BOR治疗的MM患者进行回顾性研究。我们研究了BOR的给药持续时间以及从BOR给药结束到首次LEN给药的间隔时间是否会影响LEN诱发皮疹的发生。
81例患者中有28例出现LEN诱发的皮疹（34.6%）。无皮疹组的给药持续时间显著更长，而非间隔时间。分别为给药持续时间和间隔设定了临界值，分别为35天和30天。对给药持续时间超过35天且间隔时间小于30天的患者以及不适用的患者进行多因素分析。各因素在皮疹发生率上观察到显著差异。
降低LEN诱发皮疹的风险不仅受先前是否使用BOR的影响，还受BOR的给药持续时间以及从BOR给药结束到首次LEN给药的间隔时间的影响。
